GO
Loading...

Pfizer in $2.15 Billion Settlement From Teva and Sun for Patent Infringement

CNBC With Reuters
Wednesday, 12 Jun 2013 | 8:37 AM ET

Pfizer settled a nearly 10-year battle Wednesday, announcing a $2.15 billion settlement with Teva Pharmaceuticals Industries and Sun Pharmaceutical Industries for patent infringement on its acid-reflux drug Protonix.

Japan's Takeda Pharmaceutical Co Ltd, Pfizer's partner on the drug, will receive 36 percent or about $774 million from the settlement.

Pfizer won a protracted 10-year legal battle in April 2010 when a New Jersey jury ruled that Teva had infringed the Protonix patent. Teva started selling a generic version of the drug in 2007.

A trial to determine damages began on Monday.

(Read More: Options Action: A Bullish Bet on Pfizer)

Cramer: Yes, I Like Pfizer
Drug stocks have been roaring since the beginning of the year. Mad Money host Jim Cramer has been dishing out pharma opportunities all week, and tonight he recommends Pfizer.

The patent was held by Nycomed—now a Takeda subsidiary. Protonix was licensed to Wyeth, which is now owned by Pfizer.

Israel-based Teva, the world's largest generic drugmaker, will pay $1.6 billion—half this year and the rest by October 2014. India's Sun Pharma will pay $550 million this year.

Teva said in February that it may face legal losses of up to $2.07 billion to resolve the case.

Sun Pharma set aside 5.84 billion rupees, or about $100 million, last November towards potential damages to Pfizer. The company will now have to shell out a further $450 million as final settlement.

"This is not a very positive out-of-court settlement. The agreed amount is way too high for such a settlement," said Daljeet Kohli, head of research at brokerage IndiaNivesh in Mumbai. "It will also restrict Sun's ability to look for acquisitions."

Pfizer's shares traded up about 1 percent at $28.66 before the bell, while Teva's U.S.-listed shares were down about 1 percent at $39.51. Sun Pharma closed little changed at 980.70 rupees, while Takeda's stock closed down 1.4 percent at 4,355 yen.

Reuters contributed to this report.

  Price   Change %Change
TEVA
---
PFE
---